Welsh hospitals extend routine MT-RNR1 testing

Genedrive's neonatal test adoption grows, but commercial impact hinges on 2027 NHS decisions.

What the company is saying

Genedrive plc highlights the extension of routine clinical use of its MT-RNR1 genetic test in Welsh hospitals, specifically Betsi Cadwaladr University Health Board and Cardiff and Vale University Health Board. The company frames this as evidence of growing adoption within the NHS, emphasizing that seven of fourteen PALOH-UK sites have now moved to routine clinical service. The announcement stresses that nearly 6,000 babies have been tested to date, with more than 40 identified as carrying the MT-RNR1 variant, supporting the test's clinical relevance. Genedrive positions the extension as funded through July 2027, pending a final NICE assessment, and underscores anticipated NHS England procurement milestones in 2027. The tone is confident and forward-looking, with CEO Dr Gino Miele quoted to reinforce the company's role in integrating rapid pharmacogenetic testing into neonatal care. The release downplays financial specifics and focuses on operational and regulatory progress.

What the data suggests

The announcement confirms that seven of fourteen UK sites in the PALOH-UK programme have transitioned to routine clinical use of the Genedrive MT-RNR1 test. Patient recruitment for the programme is complete, with nearly 6,000 babies tested, and over 40 identified with the MT-RNR1 variant, indicating tangible clinical uptake. The two Welsh hospitals extending service represent approximately 750 NICU admissions annually, but no revenue or cost figures are disclosed. Funding for the extension is stated as secured from May 2026 to July 2027, but the amount is not specified. The test has exited NICE's Early Value Assessment and is now under technology appraisal, with a conditional NICE recommendation in place. NHS England's procurement process is not expected to begin until January 2027, with a go-live target of July 2027, both contingent on the outcome of NICE guidance. The data shows operational progress and clinical adoption but leaves the financial impact and commercial trajectory unquantified.

Analysis

The announcement presents a positive tone, highlighting clinical adoption progress and future regulatory milestones for the Genedrive® MT-RNR1 ID kit. Several realised facts are disclosed, such as 7 of 14 sites transitioning to routine clinical service and nearly 6,000 babies tested, which demonstrate operational progress. However, many key claims—including the extension of service, future funding, NICE assessment, and NHS England procurement—are forward-looking and contingent on events not expected to resolve until mid-2027, well beyond the near term. No financial figures (revenue, profit, cost, or funding amounts) are disclosed, and the financial impact of these milestones is not quantified. The language is moderately promotional, emphasizing adoption and anticipated regulatory catalysts, but the absence of financial data and the long timeline to potential commercial benefit limit the strength of the signal. The gap between narrative and evidence is moderate: operational progress is real, but the investment case remains unproven without financial metrics.

Risk flags

• ●Commercialisation risk remains high, as NHS England procurement and widespread adoption are contingent on a final NICE assessment in July 2027. Until then, revenue from routine clinical use is likely limited to pilot or early adopter sites.
• ●Financial transparency is lacking, with no disclosed figures for revenue, funding amounts, or cost structure. This makes it difficult for investors to assess the scale or profitability of current or future operations.
• ●Execution risk is present in the long timeline to potential NHS-wide adoption, with key decisions and tender processes not commencing until 2027. Delays or negative outcomes from NICE or NHS England could materially impact the company's prospects.

Bottom line

Genedrive's MT-RNR1 test is seeing increased clinical adoption in the UK, with seven of fourteen PALOH-UK sites now using it routinely and nearly 6,000 babies tested. The extension of service in Welsh hospitals is funded through July 2027, but the absence of disclosed revenue or funding amounts leaves the commercial impact unclear. The company's future hinges on the outcome of a final NICE assessment and subsequent NHS England procurement, both scheduled for mid-2027. Until those milestones are reached, the investment case rests on operational progress rather than proven financial returns. Investors should focus on the October 2026 publication of clinical cohort analysis and monitor for any updates on NICE and NHS England timelines. The most important takeaway is that while adoption is growing, meaningful commercial returns are unlikely before the second half of 2027.

Announcement summary

(AIM:GDR) genedrive plc announced that Betsi Cadwaladr University Health Board and Cardiff and Vale University Health Board will extend routine clinical service of the Genedrive® MT-RNR1 ID kit for the prevention of Antibiotic Induced Hearing Loss in neonates admitted to Neonatal Intensive Care Units, with continuation funded from 1 May 2026 until the outcome of the final NICE assessment expected in July 2027. These hospitals represent approximately 750 NICU admissions annually and are two of the 14 sites participating in the PALOH-UK programme, which was established to address NICE Real World Evidence generation requirements. Seven of the 14 UK sites participating in the PALOH-UK Programme have now transitioned to routine clinical service, demonstrating growing adoption of Genedrive® MT-RNR1 in NHS neonatal care. Patient recruitment in the PALOH-UK programme has been completed, with nearly 6,000 babies in neonatal care receiving the Genedrive® MT-RNR1 ID test. Since the introduction of the test in the UK, more than 40 critically ill babies have been identified with the MT-RNR1 variant, allowing clinicians to prescribe an alternative antibiotic and helping to prevent AIHL. Clinical cohort analysis is underway with publication expected in scientific literature around October 2026. Funding for PALOH-UK sites is provided by the Office for Life Sciences and National Institute for Health and Care Research. The Genedrive® MT-RNR1 ID Kit has exited NICE's Early Value Assessment pathway and has been selected for technology appraisal following ministerial referral from the Department of Health and Social Care. The test currently has a conditional NICE recommendation. NHS England has communicated an anticipated tender notice publication date of 1 January 2027 and a go-live target of July 2027, subject to the outcome of NICE guidance.

Disagree with this article?